On September 15, 2022, Arns, Stephen Paul; Hsieh, Tom Han Hsiao; Shidmoossavee, Fahimeh S.; Tan, Jason Samuel; Yee, Leanna; Paquette, Jay John; Jaquith, James Brian; Osborne, Simon; Smiljanic-Hurley, Ela; Hamby, Callum; Smyth, Elliott; Ambler, Martin; Minchinton, Andrew I.; Kyle, Alastair H.; Baker, Jennifer H. E. published a patent.Recommanded Product: 596114-50-0 The title of the patent was Preparation of 7-morpholino-1,6-naphthyridin-5-yl derivatives and use thereof as DNA-PK inhibitors. And the patent contained the following:
The present disclosure provides compounds of formula I and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. Compounds of formula I wherein R1a is H and C1-6 alkyl; R1b is C1-6 alkyl, C3-8 cycloalkyl, 3-8 heterocycloalkyl, etc.; R2 is halo, cyano, C1-6 alkyl, etc.; R3 is H, halo, C1-6 alkyl and C1-6 haloalkyl; R4 is C1-6 alkyl and C1-6 haloalkyl; and their pharmaceutically acceptable salts, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their DNA-PK inhibitory activity (data given). The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Recommanded Product: 596114-50-0
The Article related to morpholino naphthyridinyl preparation dna protein kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Recommanded Product: 596114-50-0
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia